NextCell Pharma (Sweden) Today
| NXTCL Stock | SEK 1.51 0.06 4.14% |
Performance2 of 100
| Odds Of DistressOver 68
|
NextCell Pharma is selling for under 1.51 as of the 11th of June 2024; that is 4.14 percent up since the beginning of the trading day. The stock's lowest day price was 1.38. NextCell Pharma has more than 68 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for NextCell Pharma AB are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 13th of March 2024 and ending today, the 11th of June 2024. Click here to learn more.
NextCell Pharma AB operates as a tissue establishment and primary biobank in Sweden. NextCell Pharma AB was founded in 2014 and is based in Huddinge, Sweden. NextCell Pharma operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. The company has 34.38 M outstanding shares. More on NextCell Pharma AB
Moving together with NextCell Stock
Moving against NextCell Stock
Valuation
Check how we calculate scores
NextCell Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. NextCell Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding NextCell Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
NextCell Pharma AB (NXTCL) is traded on Stockholm Exchange in Sweden and employs 15 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 255.91 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate NextCell Pharma's market, we take the total number of its shares issued and multiply it by NextCell Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. NextCell Pharma AB operates under Healthcare sector and is part of Biotechnology industry. The entity has 34.38 M outstanding shares.
NextCell Pharma AB has accumulated about 150.75 M in cash with (33.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check NextCell Pharma Probability Of Bankruptcy
Ownership AllocationNextCell Pharma AB holds a total of 34.38 Million outstanding shares. NextCell Pharma AB holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check NextCell Ownership Details
NextCell Pharma AB Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. NextCell Pharma market risk premium is the additional return an investor will receive from holding NextCell Pharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in NextCell Pharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although NextCell Pharma's alpha and beta are two of the key measurements used to evaluate NextCell Pharma's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 8.75 | |||
| Semi Deviation | 11.47 | |||
| Standard Deviation | 24.59 | |||
| Variance | 604.75 |
NextCell Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in NextCell Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Insider Screener Now
Insider ScreenerFind insiders across different sectors to evaluate their impact on performance |
| All Next | Launch Module |
NextCell Pharma Corporate Management
Elected by the shareholders, the NextCell Pharma's board of directors comprises two types of representatives: NextCell Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NextCell. The board's role is to monitor NextCell Pharma's management team and ensure that shareholders' interests are well served. NextCell Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NextCell Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sofie Jansson | Marketing Director | Profile | |
| Mathias Svahn | Founder CEO | Profile | |
| Anders MSc | Chairman | Profile | |
| Edvard Smith | Medical Director | Profile | |
| Patrik Fagerholm | Chief Officer | Profile | |
| Lindsay Davies | Chief Officer | Profile |
Additional Tools for NextCell Stock Analysis
When running NextCell Pharma's price analysis, check to measure NextCell Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NextCell Pharma is operating at the current time. Most of NextCell Pharma's value examination focuses on studying past and present price action to predict the probability of NextCell Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NextCell Pharma's price. Additionally, you may evaluate how the addition of NextCell Pharma to your portfolios can decrease your overall portfolio volatility.